NeuroSense Therapeutics provided a further update on its plans to file for early commercialization approval for PrimeC under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy.
- Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026
- Estimated potential market opportunity: peak of $100M to $150M in annual revenue
- Company aims to expand approval efforts to additional global markets
